[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : REDUCE-IT, global cardiovascular outcome study designed to assess cardioprotective efficacy and safety of VASCEPA (icosapent ethyl), a unique form of eicosapentaenoic acid, as an add-on to statin therapy in reducing major cardiovascular event in a high-r...

                          Product Name : Vascepa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2022

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : MedStar Health Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Vascepa (Icosapent ethyl) 4 g/day significantly reduced total primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD.

                          Product Name : Vascepa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2021

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The investigators concluded that, “Icosapent ethyl 4 g/day significantly reduced total (first and subsequent) primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD.

                          Product Name : Vascepa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 15, 2021

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months.

                          Product Name : Vascepa

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 17, 2021

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank